223 related articles for article (PubMed ID: 33529593)
1. Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
Yu HJ; Ehlers JP; Sevgi DD; Hach J; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
Am J Ophthalmol; 2021 Jun; 226():126-136. PubMed ID: 33529593
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
[TBL] [Abstract][Full Text] [Related]
3. Real-Time Diabetic Retinopathy Severity Score Level versus Ultra-Widefield Leakage Index-Guided Management of Diabetic Retinopathy: Two-Year Outcomes from the Randomized PRIME Trial.
Yu HJ; Ehlers JP; Sevgi DD; O'Connell M; Reese JL; Srivastava SK; Wykoff CC
J Pers Med; 2021 Sep; 11(9):. PubMed ID: 34575662
[TBL] [Abstract][Full Text] [Related]
4. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
[TBL] [Abstract][Full Text] [Related]
5. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.
Staurenghi G; Feltgen N; Arnold JJ; Katz TA; Metzig C; Lu C; Holz FG;
Br J Ophthalmol; 2018 Jul; 102(7):954-958. PubMed ID: 29051325
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
[TBL] [Abstract][Full Text] [Related]
7. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
Kalra G; Wykoff C; Martin A; Srivastava SK; Reese J; Ehlers JP
Ophthalmol Retina; 2024 Feb; 8(2):116-125. PubMed ID: 37696393
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
[TBL] [Abstract][Full Text] [Related]
10. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
11. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
13. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.
Wykoff CC; Nittala MG; Zhou B; Fan W; Velaga SB; Lampen SIR; Rusakevich AM; Ehlers JP; Babiuch A; Brown DM; Ip MS; Sadda SR;
Ophthalmol Retina; 2019 Dec; 3(12):1076-1086. PubMed ID: 31542339
[TBL] [Abstract][Full Text] [Related]
15. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial.
Kanar HS; Arsan A; Altun A; Akı SF; Hacısalihoglu A
Indian J Ophthalmol; 2020 Jan; 68(1):145-151. PubMed ID: 31856493
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
[TBL] [Abstract][Full Text] [Related]
17. Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies.
Korobelnik JF; Lu C; Katz TA; Dhoot DS; Loewenstein A; Arnold J; Staurenghi G
Ophthalmol Retina; 2019 Aug; 3(8):663-669. PubMed ID: 31103642
[TBL] [Abstract][Full Text] [Related]
18. RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY.
Babiuch AS; Wykoff CC; Srivastava SK; Talcott K; Zhou B; Hach J; Hu M; Reese JL; Ehlers JP
Retina; 2020 Nov; 40(11):2175-2183. PubMed ID: 31917731
[TBL] [Abstract][Full Text] [Related]
19. Widefield OCT-Angiography and Fluorescein Angiography Assessments of Nonperfusion in Diabetic Retinopathy and Edema Treated with Anti-Vascular Endothelial Growth Factor.
Couturier A; Rey PA; Erginay A; Lavia C; Bonnin S; Dupas B; Gaudric A; Tadayoni R
Ophthalmology; 2019 Dec; 126(12):1685-1694. PubMed ID: 31383483
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
Clark WL; Boyer DS; Heier JS; Brown DM; Haller JA; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Campochiaro PA
Ophthalmology; 2016 Feb; 123(2):330-336. PubMed ID: 26522708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
